CW September 2004
Volume 13Issue Number 9 September 2004 ISSN 10593802 A New Approach to Pain TherapyA novel monoclonal antibody that blocks Nerve Growth Factor (NGF), a key mediator of pain, enters Phase 1 clinical study.
Go to Previous Page Go to Next Page Source & Additional Reading Franz Hefti, executive vice president of development at Rinat. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW September 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
